KALV Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 12.30%

Insider Buying (Last 12 Months): $5,806,280.30

Insider Selling (Last 12 Months): $2,650,351.15

KalVista Pharmaceuticals Insider Trading History Chart

KalVista Pharmaceuticals Share Price & Price History

^$12.06

▼ -0.13 (-1.07%)

As of 05/8/2024 01:00 AM ET

Days: 30 | 90 | 365

Did You Get Your Free Bitcoin Yet?

From Crypto Swap Profits | Ad

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

KalVista Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/20/2024	Benjamin L Palleiko	CFO	Sell	22,802	$14.11	$321,736.22	187,315
2/20/2024	Edward P. Feener	Insider	Sell	28,288	$14.07	$398,012.16	62,157
2/20/2024	Thomas Andrew Crockett	CEO	Sell	24,888	$14.11	$351,169.68	211,203
2/8/2024	Venrock Healthcare Capital Par	Major Shareholder	Buy	29,747	$14.70	$437,280.90	4,824,731
2/6/2024	Venrock Healthcare Capital Par	Major Shareholder	Buy	4,474	$14.74	$65,946.76	4,743,157
1/29/2024	Venrock Healthcare Capital Par	Major Shareholder	Buy	80,600	$14.22	$1,146,132.00	4,650,584
1/26/2024	Venrock Healthcare Capital Par	Major Shareholder	Buy	4,174	$12.98	$54,178.52	4,569,984
1/24/2024	Venrock Healthcare Capital Par	Major Shareholder	Buy	20,686	$12.44	$257,333.84	4,558,780
1/22/2024	Venrock Healthcare Capital Par	Major Shareholder	Buy	67,546	$12.55	$847,702.30	4,527,197
1/18/2024	Venrock Healthcare Capital Par	Major Shareholder	Buy	39,680	$12.51	$496,396.80	4,434,651
1/16/2024	Venrock Healthcare Capital Par	Major Shareholder	Buy	19,599	$12.73	$249,495.27	4,316,046
1/11/2024	Edward P. Feener	Insider	Sell	22,679	$13.03	$295,507.37	39,828
1/10/2024	Venrock Healthcare Capital Par	Major Shareholder	Buy	47,700	$12.67	$604,359.00	4,289,800
1/8/2024	Edward P. Feener	Insider	Sell	17,221	$13.01	$224,045.21	62,607
1/8/2024	Venrock Healthcare Capital Par	Major Shareholder	Buy	69,184	$12.44	$860,648.96	4,221,284
1/3/2024	Venrock Healthcare Capital Par	Major Shareholder	Buy	17,605	$12.20	$214,781.00	4,110,336
12/29/2023	Venrock Healthcare Capital Par	Major Shareholder	Buy	6,013	$12.49	$75,102.37	4,092,731
12/27/2023	Thomas Andrew Crockett	CEO	Sell	30,000	$12.02	$360,600.00	127,532
12/27/2023	Venrock Healthcare Capital Par	Major Shareholder	Buy	41,514	$11.97	$496,922.58	3,615,228
9/11/2023	Albert Cha	Director	Sell	18,000	$10.50	$189,000.00
8/18/2023	Benjamin L Palleiko	CFO	Sell	13,067	$10.73	$140,208.91	95,254
8/18/2023	Paul K Audhya	Insider	Sell	8,020	$10.73	$86,054.60	26,023
8/18/2023	Thomas Andrew Crockett	CEO	Sell	14,876	$10.73	$159,619.48	146,756
5/18/2023	Benjamin L Palleiko	CFO	Sell	4,037	$10.14	$40,935.18	78,126
5/18/2023	Christopher Yea	Insider	Sell	2,604	$10.14	$26,404.56	37,310
5/18/2023	Thomas Andrew Crockett	CEO	Sell	5,627	$10.14	$57,057.78	128,050
2/17/2023	Benjamin L Palleiko	CFO	Sell	4,954	$7.66	$37,947.64	72,799
2/17/2023	Paul K Audhya	Insider	Sell	3,412	$7.66	$26,135.92	9,347
2/17/2023	Thomas Andrew Crockett	CEO	Sell	6,700	$7.66	$51,322.00	120,927
11/18/2022	Benjamin L Palleiko	CFO	Sell	722	$5.44	$3,927.68	68,390
11/18/2022	Christopher Yea	Insider	Sell	1,139	$5.44	$6,196.16	34,232
11/18/2022	Thomas Andrew Crockett	CEO	Sell	1,785	$5.44	$9,710.40	114,878
8/17/2022	Thomas Andrew Crockett	CEO	Sell	1,797	$14.96	$26,883.12	112,178
3/9/2022	Thomas Andrew Crockett	CEO	Sell	10,000	$17.07	$170,700.00
11/1/2021	Edward P. Feener	Insider	Sell	6,000	$18.07	$108,420.00
10/1/2021	Thomas Andrew Crockett	CEO	Sell	10,000	$17.18	$171,800.00
8/2/2021	Christopher Yea	Insider	Sell	5,000	$20.52	$102,600.00	8,234
7/1/2021	Thomas Andrew Crockett	CEO	Sell	10,000	$24.15	$241,500.00
6/17/2021	Thomas Andrew Crockett	CEO	Sell	1,067	$30.04	$32,052.68	144,670
6/9/2021	Thomas Andrew Crockett	CEO	Sell	8,933	$30.05	$268,436.65

Trump’s “Tax Free” Retirement Strategy

From Gold Safe Exchange | Ad

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

Protect your retirement savings from the inevitable devaluation of the dollar…

SEC Filings (Institutional Ownership Changes) for KalVista Pharmaceuticals (NASDAQ:KALV)

Institutional Buying and Selling by Quarter

KalVista Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/8/2024	Entropy Technologies LP	10,172	$0.12M	0.0%	N/A	0.024%
5/7/2024	Susquehanna Fundamental Investments LLC	16,179	$0.19M	0.0%	N/A	0.038%
5/7/2024	ClariVest Asset Management LLC	55,561	$0.66M	0.1%	N/A	0.132%
5/7/2024	SG Americas Securities LLC	12,082	$0.14M	0.0%	-91.2%	0.029%
5/1/2024	BNP Paribas Financial Markets	18,013	$0.21M	0.0%	+94.5%	0.043%
4/29/2024	Principal Financial Group Inc.	10,234	$0.12M	0.0%	-11.2%	0.024%
4/29/2024	China Universal Asset Management Co. Ltd.	8,024	$95K	0.0%	+101.6%	0.019%
4/25/2024	Rosalind Advisors Inc.	287,985	$3.42M	3.2%	-4.0%	0.683%
2/15/2024	Opaleye Management Inc.	150,000	$1.84M	0.5%	-70.0%	0.434%
2/15/2024	Frazier Life Sciences Management L.P.	3,622,294	$44.37M	2.4%	+11.8%	10.481%
2/13/2024	Tower Research Capital LLC TRC	3,482	$43K	0.0%	+28.3%	0.010%
2/13/2024	Affinity Asset Advisors LLC	125,969	$1.54M	0.3%	-54.7%	0.364%
2/13/2024	Campbell & CO Investment Adviser LLC	41,365	$0.51M	0.0%	N/A	0.120%
2/6/2024	AJOVista LLC	4,920	$60K	0.1%	N/A	0.014%
1/24/2024	Mirae Asset Global Investments Co. Ltd.	10,260	$0.13M	0.0%	N/A	0.030%
1/24/2024	China Universal Asset Management Co. Ltd.	3,981	$49K	0.0%	N/A	0.012%
1/12/2024	SG Americas Securities LLC	137,817	$1.69M	0.0%	+5.1%	0.399%
12/18/2023	Vanguard Group Inc.	1,732,489	$16.68M	0.0%	+9.6%	5.013%
11/15/2023	Adage Capital Partners GP L.L.C.	1,056,691	$10.18M	0.0%	-4.3%	3.072%
11/15/2023	Affinity Asset Advisors LLC	278,292	$2.68M	0.8%	+56.1%	0.809%
11/14/2023	MPM Bioimpact LLC	577,958	$5.57M	1.5%	-24.1%	1.680%
11/14/2023	Nan Fung Group Holdings Ltd	234,573	$2.26M	1.8%	+14.6%	0.682%
11/13/2023	Connor Clark & Lunn Investment Management Ltd.	104,668	$1.01M	0.0%	-3.1%	0.304%
11/13/2023	Algert Global LLC	23,250	$0.22M	0.0%	-11.6%	0.068%
11/13/2023	Rathbones Group PLC	19,022	$0.18M	0.0%	N/A	0.055%
11/9/2023	Citigroup Inc.	276,918	$2.67M	0.0%	-7.6%	0.805%
11/7/2023	Quantbot Technologies LP	3,200	$31K	0.0%	N/A	0.009%
11/7/2023	New York State Common Retirement Fund	9,959	$96K	0.0%	+1,860.4%	0.029%
11/7/2023	Jump Financial LLC	10,200	$98K	0.0%	-62.4%	0.030%
11/2/2023	Principal Financial Group Inc.	11,344	$0.11M	0.0%	N/A	0.033%
10/31/2023	Panagora Asset Management Inc.	22,941	$0.22M	0.0%	-12.1%	0.067%
10/26/2023	Strs Ohio	10,800	$0.10M	0.0%	N/A	0.031%
10/24/2023	Bank of New York Mellon Corp	84,309	$0.81M	0.0%	+1.8%	0.245%
10/13/2023	SG Americas Securities LLC	131,147	$1.26M	0.0%	+8.1%	0.381%
9/21/2023	Barclays PLC	4,906	$44K	0.0%	-60.5%	0.014%
8/21/2023	Affinity Asset Advisors LLC	178,292	$1.61M	0.6%	-14.4%	0.520%
8/15/2023	Silverarc Capital Management LLC	720,508	$6.49M	2.0%	-0.4%	2.105%
8/15/2023	Suvretta Capital Management LLC	2,034,506	$18.31M	1.0%	+2.6%	5.944%
8/14/2023	Jefferies Financial Group Inc.	1,030,000	$9.27M	0.1%	-14.2%	3.009%
8/14/2023	Driehaus Capital Management LLC	1,035,935	$9.32M	0.1%	+2.1%	3.026%
8/11/2023	Nan Fung Group Holdings Ltd	204,720	$1.84M	1.2%	+160.1%	0.598%
8/11/2023	Panagora Asset Management Inc.	26,090	$0.24M	0.0%	-43.6%	0.076%
8/11/2023	ExodusPoint Capital Management LP	31,180	$0.28M	0.0%	N/A	0.091%
8/10/2023	Citigroup Inc.	299,808	$2.70M	0.0%	+8.3%	0.876%
8/8/2023	AlphaCentric Advisors LLC	135,000	$1.22M	0.7%	N/A	0.394%
8/7/2023	Acadian Asset Management LLC	8,736	$78K	0.0%	-94.7%	0.026%
8/4/2023	Cibc World Markets Corp	50,000	$0.45M	0.0%	N/A	0.146%
8/3/2023	Los Angeles Capital Management LLC	72,540	$0.65M	0.0%	N/A	0.212%
8/1/2023	Choate Investment Advisors	10,000	$90K	0.0%	N/A	0.029%
7/18/2023	Denali Advisors LLC	29,200	$0.26M	0.1%	+403.4%	0.085%
7/10/2023	SG Americas Securities LLC	121,353	$1.09M	0.0%	N/A	0.355%
5/16/2023	Great Point Partners LLC	1,600,545	$12.58M	2.5%	+51.6%	4.684%
5/16/2023	Boxer Capital LLC	1,650,000	$12.97M	0.6%	N/A	4.829%
5/15/2023	Affinity Asset Advisors LLC	208,292	$1.64M	0.5%	+10.6%	0.610%
5/15/2023	Suvretta Capital Management LLC	1,983,179	$15.59M	0.7%	+84.9%	5.804%
5/12/2023	Prosight Management LP	240,000	$1.89M	0.9%	-61.4%	0.702%
5/11/2023	Acadian Asset Management LLC	164,671	$1.29M	0.0%	-67.6%	0.482%
5/10/2023	Connor Clark & Lunn Investment Management Ltd.	99,871	$0.79M	0.0%	+6.9%	0.292%
4/21/2023	Denali Advisors LLC	5,800	$46K	0.0%	-46.3%	0.017%
2/15/2023	Tang Capital Management LLC	3,196,446	$21.61M	3.1%	+77.6%	12.984%
2/15/2023	Jefferies Financial Group Inc.	1,200,000	$8.11M	0.1%	N/A	4.874%
2/14/2023	VR Adviser LLC	2,916,667	$19.72M	3.2%	N/A	11.847%
2/14/2023	Pura Vida Investments LLC	732,702	$4.95M	0.3%	-12.0%	2.976%
2/14/2023	Driehaus Capital Management LLC	1,011,371	$6.84M	0.1%	+91.0%	4.108%
2/13/2023	Vivo Capital LLC	856,008	$5.79M	0.7%	-44.2%	3.477%
2/10/2023	Opaleye Management Inc.	923,200	$6.24M	2.2%	N/A	3.750%
2/10/2023	Connor Clark & Lunn Investment Management Ltd.	93,413	$0.63M	0.0%	-2.3%	0.379%
2/10/2023	Cheyne Capital Management UK LLP	52,790	$0.36M	0.6%	N/A	0.214%
2/9/2023	Denali Advisors LLC	10,800	$73K	0.0%	N/A	0.044%
2/9/2023	Citigroup Inc.	277,071	$1.87M	0.0%	+41,315.7%	1.125%
2/9/2023	Saturn V Capital Management LLC	719,937	$6.70M	5.6%	N/A	2.924%
2/8/2023	Thrivent Financial for Lutherans	13,623	$92K	0.0%	N/A	0.055%
2/3/2023	Frazier Life Sciences Management L.P.	3,238,859	$21.90M	1.4%	+106.0%	13.155%
11/15/2022	Pura Vida Investments LLC	832,702	$12.08M	0.7%	+2.4%	3.385%
11/15/2022	Prosight Management LP	530,062	$7.69M	4.1%	-35.4%	2.155%
11/15/2022	Laurion Capital Management LP	347,125	$5.04M	0.0%	-26.1%	1.411%
11/15/2022	Eventide Asset Management LLC	276,200	$4.01M	0.1%	N/A	1.123%
11/14/2022	Point72 Asset Management L.P.	57,800	$0.84M	0.0%	N/A	0.235%
11/10/2022	Connor Clark & Lunn Investment Management Ltd.	95,586	$1.39M	0.0%	+45.1%	0.389%
11/8/2022	International Biotechnology Trust PLC	316,133	$4.59M	1.5%	+8,307.8%	1.285%
11/7/2022	Jump Financial LLC	12,200	$0.18M	0.0%	-47.2%	0.050%
10/27/2022	US Bancorp DE	2,984	$43K	0.0%	N/A	0.012%
8/19/2022	Walleye Capital LLC	204,338	$2.01M	0.1%	+218.2%	0.832%
8/16/2022	Woodline Partners LP	1,086,883	$10.70M	0.2%	+118.7%	4.424%
8/16/2022	International Biotechnology Trust PLC	3,760	$0.38M	4.0%	-99.0%	0.015%
8/16/2022	Pura Vida Investments LLC	812,828	$8M	0.5%	+1,863.7%	3.308%
8/16/2022	DAFNA Capital Management LLC	265,663	$2.61M	0.7%	+39.3%	1.081%
8/13/2022	Prosight Management LP	820,752	$8.08M	6.4%	+39.3%	3.340%
8/11/2022	Trexquant Investment LP	39,048	$0.38M	0.0%	N/A	0.159%
8/11/2022	Alps Advisors Inc.	14,561	$0.14M	0.0%	-42.3%	0.059%
8/8/2022	Walleye Capital LLC	204,338	$2.01M	0.1%	+218.2%	0.832%
8/5/2022	Connor Clark & Lunn Investment Management Ltd.	65,882	$0.65M	0.0%	+187.8%	0.268%
7/29/2022	SG Americas Securities LLC	16,691	$0.16M	0.0%	N/A	0.068%
6/30/2022	Amalgamated Bank	3,652	$54K	0.0%	N/A	0.015%
6/7/2022	Teachers Retirement System of The State of Kentucky	30,335	$0.45M	0.0%	+15.6%	0.124%
5/27/2022	Walleye Capital LLC	64,210	$0.95M	0.0%	N/A	0.262%
5/17/2022	Prosight Management LP	589,270	$8.69M	5.6%	+43.9%	2.401%
5/17/2022	Great Point Partners LLC	874,197	$12.89M	3.1%	+112.2%	3.562%
5/16/2022	Deerfield Management Company L.P. Series C	830,472	$12.24M	0.3%	-29.3%	3.384%
5/16/2022	Deep Track Capital LP	1,729,757	$25.50M	1.6%	+15.3%	7.048%

Data available starting January 2016

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $12.06

$12.00

$12.25

50 Day Range

MA: $12.01

$10.35

$14.38

52 Week Range

Now: $12.06

$7.21

$16.88

Volume

160,775 shs

Average Volume

679,818 shs

Market Capitalization

$508.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92

Who are the company insiders with the largest holdings of KalVista Pharmaceuticals?: KalVista Pharmaceuticals' top insider investors include:
Venrock Healthcare Capital Par (Major Shareholder)
Thomas Andrew Crockett (CEO)
Benjamin L Palleiko (CFO)
Edward P Feener (Insider)
Christopher Yea (Insider)
Paul K Audhya (Insider)
Albert Cha (Director)
Learn More about top insider investors at KalVista Pharmaceuticals.
Who are the major institutional investors of KalVista Pharmaceuticals?: KalVista Pharmaceuticals' top institutional shareholders include:
Rosalind Advisors Inc. — 0.68%
ClariVest Asset Management LLC — 0.13%
BNP Paribas Financial Markets — 0.04%
Susquehanna Fundamental Investments LLC — 0.04%
SG Americas Securities LLC — 0.03%
Principal Financial Group Inc. — 0.02%
Learn More about top institutional investors of KalVista Pharmaceuticals stock.
Which institutional investors are selling KalVista Pharmaceuticals stock?: In the last quarter, KALV stock was sold by these institutional investors:
SG Americas Securities LLC
Rosalind Advisors Inc.
Principal Financial Group Inc.
Within the previous year, company insiders that have sold KalVista Pharmaceuticals company stock include:
Venrock Healthcare Capital Par (Major Shareholder)
Thomas Andrew Crockett (CEO)
Benjamin L Palleiko (CFO)
Edward P Feener (Insider)
Christopher Yea (Insider)
Paul K Audhya (Insider)
Learn More investors selling KalVista Pharmaceuticals stock.
Which institutional investors are buying KalVista Pharmaceuticals stock?: During the previous quarter, KALV stock was purchased by institutional investors including:
ClariVest Asset Management LLC
Susquehanna Fundamental Investments LLC
Entropy Technologies LP
BNP Paribas Financial Markets
China Universal Asset Management Co. Ltd.